IBB
iShares Biotechnology ETFETF · Themes$198.94−$1.78 (-0.89%)as of market close, Aug 13, 2026
☾ After hours:$198.94+0.00%3:59 PM ET
IBB holdings (2026)
All 253 positions in iShares Biotechnology ETF, ranked by portfolio weight — led by AMGN at 8.2%. Weights come from the fund's own SEC N-PORT filing and update daily with prices; positions in stocks ChartRow doesn't track still appear, ranked by weight, without returns. Not investment advice.
Weights are the Mar 31, 2026 SEC filing rolled forward on each holding's price move (as of market close, Aug 13, 2026) — an estimate of today, not the filed figure. Switch the table below to see them exactly as filed.
Holdings
253
positions in the latest filing
Largest holding
8.2%
AMGN · estimated today
Top 10 weight
47%
concentration · estimated today
On ChartRow
68.0%
fund weight in tickers ChartRow tracks
Filed
Mar 31, 2026
SEC N-PORT report date
Top 10 holdings#
CompanyWeight1D
7Argenx SE
2.8%—
Sector weights#
SectorWeight
Healthcare
68.0%
Not on ChartRow
32.0%
Estimated portfolio characteristics#
P/E (trailing)
25.0
weighted harmonic
P/E (forward)
17.6
weighted harmonic
Median P/E
26.7
per member, trailing
P/B
6.2
weighted
Dividend yield
0.51%
weighted
Earnings growth
-34.6%
aggregate TTM, YoY
Avg market cap
$82B
weighted
Estimated by our own bottom-up analysis of the fund's SEC-filed holdings, covering 68% of portfolio weight (60% carries a valid trailing P/E). Funds publish similar figures on their own sites; ours are recomputed daily from public data.
IBB holdings by weight#
1–100 of 253Weightsthe Mar 31, 2026 filing rolled forward on price — an estimate (as of market close, Aug 13, 2026)
| # | Company | Weight | Price | 1D | YTD | 1Y | Mkt cap |
|---|---|---|---|---|---|---|---|
| 1 | AMGNAmgen Inc. | 8.20% | $417.93 | +0.4% | +27.7% | +46.7% | $226B |
| 2 | VRTXVertex Pharmaceuticals Incorporated | 7.91% | $516.13 | -1.8% | +13.8% | +33.1% | $131B |
| 3 | GILDGilead Sciences Inc. | 7.06% | $138.14 | +1.7% | +12.5% | +15.1% | $171B |
| 4 | REGNRegeneron Pharmaceuticals Inc. | 6.91% | $805.82 | +1.0% | +4.4% | +44.8% | $83B |
| 5 | NTRANatera Inc. | 3.45% | $310.78 | -1.6% | +35.7% | +94.5% | $45B |
| 6 | RVMDRevolution Medicines Inc. | 2.93% | $201.93 | -1.6% | +153.5% | +472.7% | $43B |
| 7 | Argenx SE | 2.82% | — | — | — | — | — |
| 8 | BIIBBiogen Inc. | 2.60% | $210.61 | +0.8% | +19.7% | +63.4% | $31B |
| 9 | ALNYAlnylam Pharmaceuticals Inc. | 2.52% | $227.00 | +1.4% | -42.9% | -47.2% | $30B |
| 10 | ILMNIllumina Inc. | 2.41% | $192.59 | -0.2% | +46.8% | +97.8% | $29B |
| 11 | INSMInsmed Incorporated | 2.27% | $126.31 | -4.5% | -27.4% | +3.5% | $28B |
| 12 | INCYIncyte Corp. | 2.00% | $120.49 | -0.2% | +22.0% | +47.6% | $24B |
| 13 | MRNAModerna Inc. | 1.94% | $63.65 | -0.0% | +115.8% | +148.1% | $25B |
| 14 | UTHRUnited Therapeutics Corporation | 1.79% | $501.11 | -2.1% | +2.8% | +66.3% | $21B |
| 15 | BeOne Medicines Ltd. | 1.78% | — | — | — | — | — |
| 16 | ROIVRoivant Sciences Ltd. | 1.49% | $36.29 | +0.4% | +67.2% | +213.7% | $26B |
| 17 | NBIXNeurocrine Biosciences Inc. | 1.24% | $150.80 | -3.6% | +6.3% | +17.0% | $15B |
| 18 | CRLCharles River Laboratories | 1.15% | $281.17 | -1.1% | +41.0% | +84.1% | $13B |
| 19 | BBIOBridgeBio Pharma Inc. | 1.14% | $81.22 | -3.1% | +6.2% | +65.5% | $16B |
| 20 | MEDPMedpace Holdings Inc. | 1.12% | $581.47 | -2.6% | +3.5% | +26.6% | $16B |
| 21 | BMRNBioMarin Pharmaceutical Inc. | 1.09% | $68.50 | -2.5% | +15.3% | +20.5% | $13B |
| 22 | Genmab A/S | 1.08% | — | — | — | — | — |
| 23 | EXELExelixis Inc. | 1.07% | $50.59 | +0.4% | +15.4% | +33.3% | $13B |
| 24 | Ionis Pharmaceuticals, Inc. | 1.02% | — | — | — | — | — |
| 25 | HALOHalozyme Therapeutics Inc. | 0.99% | $100.67 | -1.1% | +49.6% | +57.2% | $11B |
| 26 | ASNDAscendis Pharma A/S Ordinary Share | 0.95% | $246.29 | -3.6% | +15.5% | +25.7% | $15B |
| 27 | ARWRArrowhead Pharmaceuticals Inc. | 0.94% | $85.63 | -1.9% | +29.0% | +381.1% | $12B |
| 28 | TECHBio-Techne | 0.94% | $72.18 | -0.1% | +22.7% | +36.6% | $11B |
| 29 | MDGLMadrigal Pharmaceuticals Inc. | 0.89% | $507.08 | -5.4% | -12.9% | +41.2% | $12B |
| 30 | PRAXPraxis Precision Medicines Inc. | 0.81% | $368.47 | -4.6% | +25.0% | +660.4% | $10B |
| 31 | AXSMAxsome Therapeutics Inc. | 0.77% | $213.63 | -0.5% | +17.0% | +103.0% | $11B |
| 32 | CYTKCytokinetics Incorporated | 0.75% | $73.44 | -2.9% | +15.6% | +114.0% | $10B |
| 33 | Vaxcyte, Inc. | 0.69% | — | — | — | — | — |
| 34 | BioNTech SE | 0.60% | — | — | — | — | — |
| 35 | Krystal Biotech, Inc. | 0.55% | — | — | — | — | — |
| 36 | APGEApogee Therapeutics Inc. | 0.54% | $134.42 | -0.1% | +78.1% | +266.3% | $10B |
| 37 | Protagonist Therapeutics, Inc. | 0.53% | — | — | — | — | — |
| 38 | Repligen Corp. | 0.53% | — | — | — | — | — |
| 39 | Kymera Therapeutics, Inc. | 0.49% | — | — | — | — | — |
| 40 | Alkermes plc | 0.49% | — | — | — | — | — |
| 41 | Rhythm Pharmaceuticals, Inc. | 0.47% | — | — | — | — | — |
| 42 | Abivax SA | 0.46% | — | — | — | — | — |
| 43 | PTC Therapeutics, Inc. | 0.46% | — | — | — | — | — |
| 44 | Cogent Biosciences, Inc. | 0.44% | — | — | — | — | — |
| 45 | Arcellx, Inc. | 0.44% | — | — | — | — | — |
| 46 | Terns Pharmaceuticals, Inc. | 0.43% | — | — | — | — | — |
| 47 | Nuvalent, Inc. | 0.41% | — | — | — | — | — |
| 48 | Mirum Pharmaceuticals, Inc. | 0.41% | — | — | — | — | — |
| 49 | Tempus AI, Inc. | 0.40% | — | — | — | — | — |
| 50 | Xenon Pharmaceuticals, Inc. | 0.39% | — | — | — | — | — |
| 51 | Amicus Therapeutics, Inc. | 0.38% | — | — | — | — | — |
| 52 | CRISPR Therapeutics AG | 0.36% | — | — | — | — | — |
| 53 | Apellis Pharmaceuticals, Inc. | 0.35% | — | — | — | — | — |
| 54 | Scholar Rock Holding Corp. | 0.33% | — | — | — | — | — |
| 55 | ACADIA Pharmaceuticals, Inc. | 0.32% | — | — | — | — | — |
| 56 | Bruker Corp. | 0.31% | — | — | — | — | — |
| 57 | Crinetics Pharmaceuticals, Inc. | 0.30% | — | — | — | — | — |
| 58 | CG oncology, Inc. | 0.29% | — | — | — | — | — |
| 59 | Spyre Therapeutics, Inc. | 0.27% | — | — | — | — | — |
| 60 | Erasca, Inc. | 0.25% | — | — | — | — | — |
| 61 | Tarsus Pharmaceuticals, Inc. | 0.24% | — | — | — | — | — |
| 62 | Twist Bioscience Corp. | 0.23% | — | — | — | — | — |
| 63 | Centessa Pharmaceuticals plc | 0.23% | — | — | — | — | — |
| 64 | Ideaya Biosciences, Inc. | 0.23% | — | — | — | — | — |
| 65 | Denali Therapeutics, Inc. | 0.23% | — | — | — | — | — |
| 66 | Travere Therapeutics, Inc. | 0.23% | — | — | — | — | — |
| 67 | ImmunityBio, Inc. | 0.22% | — | — | — | — | — |
| 68 | Arcutis Biotherapeutics, Inc. | 0.22% | — | — | — | — | — |
| 69 | Veracyte, Inc. | 0.21% | — | — | — | — | — |
| 70 | Structure Therapeutics, Inc. | 0.21% | — | — | — | — | — |
| 71 | Edgewise Therapeutics, Inc. | 0.20% | — | — | — | — | — |
| 72 | 10X Genomics, Inc. | 0.20% | — | — | — | — | — |
| 73 | Legend Biotech Corp. | 0.20% | — | — | — | — | — |
| 74 | Newamsterdam Pharma Co. NV | 0.19% | — | — | — | — | — |
| 75 | Vera Therapeutics, Inc. | 0.19% | — | — | — | — | — |
| 76 | Dyne Therapeutics, Inc. | 0.19% | — | — | — | — | — |
| 77 | Beam Therapeutics, Inc. | 0.19% | — | — | — | — | — |
| 78 | BioCryst Pharmaceuticals, Inc. | 0.18% | — | — | — | — | — |
| 79 | Kodiak Sciences, Inc. | 0.18% | — | — | — | — | — |
| 80 | Sarepta Therapeutics, Inc. | 0.18% | — | — | — | — | — |
| 81 | Caris Life Sciences, Inc. | 0.18% | — | — | — | — | — |
| 82 | Immunovant, Inc. | 0.18% | — | — | — | — | — |
| 83 | ADMA Biologics, Inc. | 0.17% | — | — | — | — | — |
| 84 | Adaptive Biotechnologies Corp. | 0.17% | — | — | — | — | — |
| 85 | Oruka Therapeutics, Inc. | 0.17% | — | — | — | — | — |
| 86 | Syndax Pharmaceuticals, Inc. | 0.17% | — | — | — | — | — |
| 87 | Tango Therapeutics, Inc. | 0.16% | — | — | — | — | — |
| 88 | Ultragenyx Pharmaceutical, Inc. | 0.16% | — | — | — | — | — |
| 89 | Disc Medicine, Inc. | 0.16% | — | — | — | — | — |
| 90 | Agios Pharmaceuticals, Inc. | 0.15% | — | — | — | — | — |
| 91 | GRAIL, Inc. | 0.15% | — | — | — | — | — |
| 92 | Definium Therapeutics, Inc. | 0.15% | — | — | — | — | — |
| 93 | Zymeworks, Inc. | 0.15% | — | — | — | — | — |
| 94 | Arcus Biosciences, Inc. | 0.15% | — | — | — | — | — |
| 95 | Aurinia Pharmaceuticals, Inc. | 0.15% | — | — | — | — | — |
| 96 | Enliven Therapeutics, Inc. | 0.14% | — | — | — | — | — |
| 97 | Day One Biopharmaceuticals, Inc. | 0.14% | — | — | — | — | — |
| 98 | Vericel Corp. | 0.14% | — | — | — | — | — |
| 99 | Mineralys Therapeutics, Inc. | 0.13% | — | — | — | — | — |
| 100 | Alumis, Inc. | 0.13% | — | — | — | — | — |
Methodology#
Holdings and weights are sourced from the fund's portfolio as disclosed to the SEC on Form N-PORT — a public filing. Portfolio filings are quarterly (public ~60 days after quarter end), so we anchor on the latest one and roll each weight forward daily by that holding's price move, keeping the numbers current between filings; positions in stocks ChartRow doesn't track carry their filed weight unchanged and show "—" where we have no data. Returns are total returns (dividends reinvested). One row per company, not per ticker: when a fund holds more than one share class of the same company (Alphabet's GOOGL and GOOG, for example), we combine them into a single row whose weight is the sum of its classes. Past performance does not predict future returns; not investment advice.
FAQ#
- What are the top 10 holdings of IBB?
- IBB's top 10 holdings are Amgen Inc. (AMGN), 8.2%; Vertex Pharmaceuticals Incorporated (VRTX), 7.9%; Gilead Sciences Inc. (GILD), 7.1%; Regeneron Pharmaceuticals Inc. (REGN), 6.9%; Natera Inc. (NTRA), 3.4%; Revolution Medicines Inc. (RVMD), 2.9%; Argenx SE, 2.8%; Biogen Inc. (BIIB), 2.6%; Alnylam Pharmaceuticals Inc. (ALNY), 2.5%; Illumina Inc. (ILMN), 2.4% — together about 47% of the fund, per its Mar 31, 2026 SEC filing with weights rolled forward to today.
- How many holdings does IBB have?
- iShares Biotechnology ETF (IBB) held 253 positions as of its latest SEC N-PORT filing (Mar 31, 2026).
- How current are IBB's holdings?
- Funds disclose their full portfolio to the SEC on Form N-PORT; the quarter-end report becomes public about 60 days later. ChartRow anchors on the latest public filing (Mar 31, 2026) and rolls each weight forward daily by that holding's price move, so the weights shown estimate today rather than the filing date.
- Is ChartRow affiliated with IBB or BlackRock?
- No. ChartRow is independent and is not affiliated with, sponsored by, or endorsed by BlackRock or iShares Biotechnology ETF. Everything on this page is derived independently from the fund's public SEC filings; fund names and trademarks belong to their owners. For information only — not investment advice.